Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nandrolone for Cancer-Induced Malnutrition
NCT03263520Completed
- Sponsor
- Hospital Erasto Gaertner
- Start
- Feb 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of nandrolone in cancer cachexia (2 arms), sponsored by Hospital Erasto Gaertner. Primary endpoints: Muscle Mass Values by Bioelectrical Impedance Analysis at 30 days and Quality of Life Assessment at 30 days. Started Feb 2016; status: completed.
02
Drugs
nandrolone
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT03263520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263520.